Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Tufts Medical Center DUSA Pharmaceuticals, Inc. |
---|---|
Information provided by: | Tufts Medical Center |
ClinicalTrials.gov Identifier: | NCT00868088 |
Our study is designed to evaluate the efficacy of photodynamic therapy (PDT) for treatment of actinic cheilitis (AC) and as an adjunct to Mohs surgery for squamous cell carcinoma (SCC) on the lips. This study will utilize an FDA approved PDT modality (DUSA, Inc., Wilmington, MA 01887) using topical 5-amino-levulinic acid (ALA) for photosensitization followed by exposure to a Blu-U light source emitting 405-420nm wavelength light.
Condition | Intervention | Phase |
---|---|---|
Actinic Cheilitis Squamous Cell Carcinoma In-situ (SCC-is) Squamous Cell Carcinoma (SCC) Photodynamic Therapy (PDT) Mohs Surgery |
Procedure: PDT prior to Mohs surgery |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. |
Estimated Enrollment: | 34 |
Study Start Date: | July 2009 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
ALA + PDT: Active Comparator
Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
|
Procedure: PDT prior to Mohs surgery
Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC. 7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated. 3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage. 6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention. Photographs may be taken at each subject visit. |
placebo + PDT: Placebo Comparator
Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
|
Procedure: PDT prior to Mohs surgery
Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC. 7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated. 3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage. 6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention. Photographs may be taken at each subject visit. |
BACKGROUND:
SCC of the lip is commonly surrounded by extensive AC, which may affect part or all of the lip vermillion. While Mohs surgical technique with complete margin control is the preferred treatment for SCC at critical locations such as the lip, this technique is complicated by surrounding AC. AC and SCC in situ at the tumor edge make it difficult to achieve margins clear of dysplasia and as a result extra tissue beyond the invasive SCC often needs to be excised to ensure that the entire tumor is removed.
Non-surgical treatments when used alone to treat SCC give lower cure rates than surgical removal, and thus are not recommended as they place the subject at risk for recurrence and metastatic disease. Although one study reported high SCC clearance rates with PDT alone (24/25 SCCs histologically cleared), recurrence of 2 SCCs occurred and a metastasis to a LN was seen in one patient. (Kubler et al.)
Given that PDT has been shown to have significant efficacy for actinic keratoses and actinic cheilitis but is inadequate as primary treatment of lip SCC, we propose that PDT may be a useful adjunct to surgical resection, allowing for less extensive surgery after the dysplasia is addressed with PDT and potentially a lower recurrence rate. Although imiquimod and 5-FU are also used to treat cutaneous dysplasia, many favor PDT treatment due to its greater tolerability, shorter healing time, and more predictable host response.
There is significant data on the efficacy of PDT for treatment of actinic keratoses (AKs) and PDT is now FDA approved for treatment of AKs. (Piacquadio et al). Data on PDT for treatment of AC is much more limited, but small studies and case reports do indicate successful treatment of AC with regimens utilizing either topical 5-aminolevulinic acid (5-ALA), or a similar compound, methylaminopentanoate (MAL). The largest study with 5-ALA reports complete clinical clearance in 13/19 patients treated with 1 to 3 treatments of ALA plus Pulsed-dye laser (Alexiades). Sotiriou et al report that with two PDT treatments 8/10 patients had complete clinical and histologic clearance (Sotiriou). Case reports indicate similar success (Kodama; Stender). Efficacy has also been shown with MAL PDT. One study found that with two sessions of MAL + red light PDT complete histologic/ clinical clearance was seen in 7/15 cases of AC and partial clearance was seen in an additional 7/15 (Berking et al). Smaller studies and case reports have shown even higher response rates without clinical recurrence during short-term follow-up (Rossi et al; Hauschild et al). We have chosen 5-ALA plus blue light for PDT treatment in this study because it is FDA approved for treatment of AKs and ALA is available in the United States.
Specific Aims:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Joseph Kerbleski, M.D. | 617-636-7411 | jkerbleski@tuftsmedicalcenter.org |
Contact: Gary Rogers, M.D. | 617-636-8411 | grogers@tuftsmedicalcenter.org |
United States, Massachusetts | |
Tufts Medical Center, Department of Dermatology | Recruiting |
Boston, Massachusetts, United States, 02111 | |
Contact: Joseph Kerbleski, M.D. 617-636-7411 jkerbleski@tuftsmedicalcenter.org | |
Sub-Investigator: Deborah Cummins, M.D. | |
Sub-Investigator: Priya Thakker, M.D. | |
Sub-Investigator: Joseph Kerbleski, M.D. | |
Principal Investigator: Gary Rogers, M.D. |
Principal Investigator: | Gary Rogers, M.D. | Tufts Medical Center, Department of Dermatology |
Responsible Party: | Tufts Medical Center Department of Dermatology ( Gary Rogers, MD ) |
Study ID Numbers: | PDT for Lip |
Study First Received: | March 23, 2009 |
Last Updated: | August 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00868088 History of Changes |
Health Authority: | United States: Institutional Review Board |
AC SCC SCC-is PDT Mohs |
Mouth Diseases Carcinoma in Situ Epidermoid Carcinoma Cheilitis Stomatognathic Diseases Neoplasms, Squamous Cell |
Squamous Cell Carcinoma Carcinoma, Squamous Cell Actinic Cheilitis Neoplasms, Glandular and Epithelial Carcinoma |
Mouth Diseases Neoplasms Neoplasms by Histologic Type Carcinoma in Situ Cheilitis Stomatognathic Diseases |
Neoplasms, Squamous Cell Carcinoma, Squamous Cell Lip Diseases Neoplasms, Glandular and Epithelial Carcinoma |